COVID-19 Vaccine Responses Vary Among Hematological Malignancies
A systematic review and meta-analysis of 44 clinical studies published between January and August 2021, finds an overall reasonable response to COVID-19 vaccinations for patients with underlying hematological malignancies. The authors describe an urgent need for more effective regimens for high-risk patients. The study was made available as a preprint on medRxiv on November 8, 2021, and has not ye
First Look
source https://www.medscape.com/viewarticle/966288?src=rss
First Look
source https://www.medscape.com/viewarticle/966288?src=rss
Comments
Post a Comment